Stock Price & Analysis

Based on the analysis of GDRX's recent performance and market sentiment, it is a cautious buy due to its potential upside despite current challenges. The stock may be undervalued given its growth prospects and analyst optimism.

GDRX stock is predicted to reach $7-$9 in 2025, driven by new CEO Wendy Barnes' leadership and improving profitability. The stock is undervalued given its growth prospects and strong cash flow generation.

The S1 support level for GDRX Stock is $4.37 ,The R1 resistant level for GDRX Stock is $4.85.

As of the end of day on 2025-04-01, the price of GDRX Stock was $4.54.

The target price for GDRX Stock according to analyst rating is 6.61, with the highest price target at 9.00 and the lowest at 4.75. Analysts have a Moderate Buy rating on GDRX Stock overall.

The market cap of GDRX is $1.7B.

GDRX may be undervalued given its current price of $4.48 and EV/EBITDA of 11.5, which is lower than peers. Despite mixed Q4 results with revenue slightly below expectations, the company's adjusted EBITDA remains strong. Analysts maintain a Buy rating with price targets around $6-$8, indicating upside potential. Recent CFO resignation caused a stock drop, but fundamentals like positive cash flow suggest stability. Overall, GDRX appears fairly valued with room for growth.

GoodRx Holdings, Inc. provides a consumer-focused digital healthcare platform in the United States. It offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. It also equips healthcare professionals to find and prescribe affordable medications. It offers information and tools to help consumers compare prices and save on their prescription drug purchases. It operates a price comparison platform that provides consumers with geographically relevant prescription pricing and provides access to negotiated prices through its codes that can be used to save money on prescriptions across the United States (the prescription transactions offering). It also offers other healthcare products and services, including pharmaceutical manufacturer solutions, subscriptions, and telehealth services. Its subscription offerings provide additional benefits to consumers of its prescription transactions offering.

GDRX stock is predicted to reach $15-$20 by 2030, driven by its leading position in the prescription savings market and potential for expanded services. The company's strong user base and possible revenue growth could support this price target.

GDRX has a total of 694 employees.